Dexmedetomidine for the management of awake fibreoptic intubation

He, Xing‐Ying; Cao, Jianping; Shi, Xueyin

doi:10.1002/14651858.cd009798.pub2

Cited by 31 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Awake fibreoptic intubation A recently published Cochrane review 15 examined the use of dexmedetomidine for awake fibreoptic intubation. Owing to the heterogeneity of the available studies, they were unable to conduct a full meta-analysis.…”

Section: Sedation For Invasive Proceduresmentioning

confidence: 99%

Dexmedetomidine: its use in intensive care medicine and anaesthesia

Scott-Warren

Sebastian

2016

BJA Education

View full text Add to dashboard Cite

show abstract

Section: Sedation For Invasive Proceduresmentioning

confidence: 99%

Dexmedetomidine: its use in intensive care medicine and anaesthesia

Scott-Warren

Sebastian

2016

BJA Education

View full text Add to dashboard Cite

show abstract

“…It has been used for short-term sedation since the late 1990's, but has only been licensed for sedation in UK intensive care settings since 2011. It has been utilised off-license as the sole agent for emergence delirium, propofol-induced dyskinesias, awake tracheal intubation and awake craniotomy, amongst other indications [2,3]. Associated sedation is likely mediated by α 2 -adrenoceptors in the locus coeruleus of the pons, causing a dose-dependent inhibition of noradrenaline release.…”

Section: Discussionmentioning

confidence: 99%

Tardive dyskinesia and dexmedetomidine

Palmer

2018

Anaesthesia Cases

View full text Add to dashboard Cite

A 52-year-old female patient presented for a caudal epidurogram and epidural steroid injection. Patient compliance was limited by severe tardive dyskinesia secondary to previous chlorpromazine treatment. Based on a report of effectiveness in propofol-induced dyskinesias, an infusion of dexmedetomidine was used which effectively controlled the movements within a few minutes. The patient remained alert and comfortable throughout. This report highlights the pharmacology and clinical application of dexmedetomidine in this clinical scenario, and proposes potential mechanisms underlying this therapeutic effect.

show abstract

“…Dexmedetomidine is a selective alpha-2 agonist, and can cause sedation without significant respiratory depression and hypoxia [43,44]. It has more haemodynamic stability than other agents; however, one study showed 65% post-induction hypotension [45].…”

Section: Sedationmentioning

confidence: 99%